KR20220058554A - 오스테오폰틴에 대한 치료용 항체 - Google Patents

오스테오폰틴에 대한 치료용 항체 Download PDF

Info

Publication number
KR20220058554A
KR20220058554A KR1020227007828A KR20227007828A KR20220058554A KR 20220058554 A KR20220058554 A KR 20220058554A KR 1020227007828 A KR1020227007828 A KR 1020227007828A KR 20227007828 A KR20227007828 A KR 20227007828A KR 20220058554 A KR20220058554 A KR 20220058554A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227007828A
Other languages
English (en)
Korean (ko)
Inventor
티모시 마일스
로렌스 엘. 케이. 룽
마이클 제이. 모저
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
더 유나이티드 스테이츠 거번먼트 애즈 리프리젠티드 바이 더 디파트먼트 오브 베테랑스 어페어즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티, 더 유나이티드 스테이츠 거번먼트 애즈 리프리젠티드 바이 더 디파트먼트 오브 베테랑스 어페어즈 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20220058554A publication Critical patent/KR20220058554A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227007828A 2019-08-09 2020-08-07 오스테오폰틴에 대한 치료용 항체 Pending KR20220058554A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962884818P 2019-08-09 2019-08-09
US62/884,818 2019-08-09
PCT/US2020/045466 WO2021030209A1 (en) 2019-08-09 2020-08-07 Therapeutic antibodies against osteopontin

Publications (1)

Publication Number Publication Date
KR20220058554A true KR20220058554A (ko) 2022-05-09

Family

ID=74569814

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227007828A Pending KR20220058554A (ko) 2019-08-09 2020-08-07 오스테오폰틴에 대한 치료용 항체

Country Status (8)

Country Link
US (2) US12351625B2 (https=)
EP (1) EP4010369A4 (https=)
JP (1) JP7692401B2 (https=)
KR (1) KR20220058554A (https=)
CN (1) CN114867746A (https=)
AU (1) AU2020331301A1 (https=)
CA (1) CA3146092A1 (https=)
WO (1) WO2021030209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605371B2 (en) 2020-07-31 2026-04-21 The Board Of Trustees Of The Leland Stanford Junior University Combination therapy for cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4256901A (en) * 2000-03-23 2001-10-03 Glaxo Group Limited Method of screening for inhibitors of osteopontin
US20040234524A1 (en) * 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
US7241873B2 (en) * 2001-09-25 2007-07-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant anti-osteopontin antibody and use thereof
US20050040570A1 (en) * 2002-01-18 2005-02-24 Andreas Asselborn Method and device for determining the characteristics of molten metal
AU2004324192A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
EP2077325A4 (en) * 2006-09-11 2012-04-11 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
JP5339748B2 (ja) 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
CN102597001B (zh) 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
EP2914629A1 (en) * 2012-11-05 2015-09-09 MAB Discovery GmbH Method for the production of multispecific antibodies
AU2015279712B2 (en) * 2014-06-26 2021-03-25 Yale University Compositions and methods to regulate renalase in the treatment of diseases and disorders
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
WO2016154623A2 (en) 2015-03-26 2016-09-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-cd133 monoclonal antibodies and related compositions and methods
WO2018083237A1 (en) * 2016-11-03 2018-05-11 Roche Diagnostics Operations Inc. Novel anti-py520-ddr1 antibodies
US20190367602A1 (en) * 2016-12-12 2019-12-05 Synergenics, Llc Novel monoclonal antibodies to osteopontin

Also Published As

Publication number Publication date
AU2020331301A1 (en) 2022-02-24
EP4010369A1 (en) 2022-06-15
US20250361293A1 (en) 2025-11-27
CA3146092A1 (en) 2021-02-18
JP2022543657A (ja) 2022-10-13
US12351625B2 (en) 2025-07-08
CN114867746A (zh) 2022-08-05
WO2021030209A1 (en) 2021-02-18
EP4010369A4 (en) 2023-11-22
JP7692401B2 (ja) 2025-06-13
US20220324956A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US20220242949A1 (en) Anti-cd166 antibodies and uses thereof
CN102947337B (zh) 用于治疗结肠直肠癌的方法
US20200277398A1 (en) Humanized antibodies against ceacam1
JP7691720B2 (ja) 抗ヒトｃｄ７３抗体およびその適用
EP4257605A1 (en) Anti-tslp nanobody and use thereof
EP3741777A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN117447599A (zh) 对muc18特异性的抗体
TWI855014B (zh) Muc18特異性抗體
KR20180042226A (ko) 암 치료에 사용하기 위한 방사성 표지된 항체 단편
KR20170032463A (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
US20240360248A1 (en) Anti-ptk7 single-domain antibody and application thereof
US20250361293A1 (en) Therapeutic Antibodies Against Osteopontin
WO2022143550A1 (zh) 间皮素结合分子及其应用
CN113045659A (zh) 抗cd73人源化抗体
US20250152643A1 (en) Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
HK40070608A (en) Therapeutic antibodies against osteopontin
CN116769729A (zh) 靶向cd150的抗体或抗原结合片段及其应用
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
US20250367275A1 (en) Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
KR20260045855A (ko) 항-Trop2 항체, 상기 항체를 포함하는 접합체 및 이의 응용
CN117700553A (zh) 靶向c-MET的纳米抗体、药物偶联物及其用途
CN121591898A (zh) 靶向cd228的抗体和抗体-药物偶联物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000